若生智能
Drug Database
ME

meningococcal B vaccine (rLP 2086 / PF05212366 / MnB rLP2086)

✓ Approved

Pfizer, Inc. · · 重组蛋白

什么是 meningococcal B vaccine？

meningococcal B vaccine 是一种重组蛋白，由Pfizer, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名rLP 2086, PF05212366, MnB rLP2086
公司Pfizer, Inc.
药物类别重组蛋白, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Pfizer, Inc.

作用机制

分子靶点

meningococcal B vaccine 作用于 1 个分子靶点：

()
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

meningococcal B vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedVaccines2026-07-27

Improving Family Physicians' Vaccine Recommendation Behaviors for Non-Routine Vaccines (Meningococcal, Rotavirus, and HPV): A Two-Phase Intervention Study in Primary Care in Turkey.

Kilinç Özge Ö, Ünlü Ufuk U

In Turkey, meningococcal, rotavirus, and HPV vaccines are not included in the national schedule. We aimed to assess whether a face-to-face educational intervention could improve physicians' knowledge about these vaccines and influence their subsequent counseling and recommendation practices. We used a two-phase intervention with pre/post assessment and a 4-6-week follow-up among family physicians. In Phase 1, participants received an in-person structured educational intervention on meningococcal, rotavirus, and HPV vaccines, and their knowledge was evaluated using identical true/false tests administered before and after the session. Phase 2, conducted 4-6 weeks later, measured changes in physicians' self-reported frequency of providing recommendations about these vaccines, and whether they or their first-degree relatives had received any of the vaccines after the structured educational intervention. Differences in paired proportions were analyzed using McNemar's test (p < 0.05). Ninety-one physicians completed Phase-1; 70 from the same cohort completed Phase-2. Following the educational intervention, correct responses increased across multiple items: e.g., "Rotavirus vaccine is live" 89.0%→100% (p = 0.002); "Only humans are reservoir for meningococcal infection" 50.6%→96.7% (p < 0.001); "Meningococcal vaccine cannot be co-administered" (false) 70.3%→96.7% (p < 0.001). Phase-2 showed more proactive practice: for HPV, 52.9% reported recommending it "upon family request" and 27.1% "at every visit"; for rotavirus, these were 37.1% and 35.7%, respectively. Overall, 52.9% reported having administered one of the three vaccines to themselves or first-degree relatives after structured educational intervention; 62.2% rated the educational intervention's influence on that decision as 10/10. A structured educational intervention improved family physicians' knowledge and was associated with more proactive vaccine counseling and recommendation practices.

PMID 42506653
阅读全文 →
PubMedVaccines2026-07-27

Hepatitis B Vaccination in People Living with HIV: Bridging the Immunological Gap.

Radi Christelle C, Abu Faraj Jana J, Idriss Jad J, Gromer Daniel J DJ et al.

Hepatitis B virus (HBV) infection remains a major driver of liver-related morbidity and mortality among people living with HIV (PLWH), yet vaccine-induced protection is frequently suboptimal. HIV-associated immune dysfunction, including CD4+ T-cell depletion, altered antigen presentation, impaired T follicular helper cell support, and B-cell dysregulation, reduces seroprotection after standard recombinant HBV vaccines and may limit durability of antibody responses. Vaccine response is further influenced by HIV viral suppression, age, comorbidities, prior vaccine history, and baseline HBV serologic status, including isolated hepatitis B core antibody (anti-HBc) and occult HBV infection (OBI) considerations. Although antiretroviral therapy (ART) improves vaccine responsiveness, many PLWH fail to achieve protective hepatitis B surface antibody (anti-HBs) titers (≥10 mIU/mL) after conventional schedules, or experience antibody waning over time. Current guidelines recommend HBV vaccination for all susceptible PLWH with post-vaccination serologic testing and revaccination for nonresponders. Persistent implementation barriers, including incomplete series, vaccine hesitancy, stigma, and logistical constraints, continue to limit real-world impact. Emerging clinical trial data support CpG-adjuvanted HBV vaccines (HepB-CpG/Heplisav-B) and intensified dosing and schedules (double-dose or four-dose regimens) to improve seroprotection and generate higher peak anti-HBs titers, which may enhance durability. This review synthesizes guideline recommendations, immunologic mechanisms of hyporesponsiveness, predictors of vaccine response, and practical strategies to optimize HBV vaccination in PLWH.

PMID 42506660
阅读全文 →
PubMedVaccines2026-07-27

Influenza B Vaccines: Current Landscape and Novel Development Strategies.

Kotlyarov Roman Y RY, Ravin Nikolai V NV, Mardanova Eugenia S ES

Influenza B virus (IBV) represents a significant global health threat, contributing 20-30% of annual influenza cases and causing substantial morbidity and mortality across all age groups. Current seasonal vaccines demonstrate variable effectiveness, highlighting the urgent need for next-generation approaches that provide enhanced and sustained protection against both IBV lineages. Moreover, continuous antigenic drift of circulating viruses progressively reduces the match between vaccine-induced antibodies and contemporary strains, necessitating broad-spectrum protection strategies. This review discusses influenza B virus control strategies, encompassing both conventional approaches and emerging vaccine technologies. While antiviral therapy, epidemiological surveillance, diagnostics, and non-pharmaceutical public-health measures are integral components of influenza B control, the present review focuses specifically on vaccine-based strategies. By critically appraising the available evidence, this review evaluates the extent to which these strategies may improve the effectiveness of IBV vaccines and, in the longer term, inform the prospect of reducing the burden of-or potentially eliminating-influenza B virus, a goal that remains hypothetical and requires clinical validation.

PMID 42506610
阅读全文 →
PubMedEmerging microbes & infections2026-07-27

Human pulmonary infection by Brucella suis vaccine strain S2 revealed by genome sequencing in China.

Li Kun K, Zhou Xiaoyan X, Tian Lingling L, Wu Leyu L et al.

Brucellosis the most common zoonosis worldwide. For control and prevention of animal brucellosis, various Brucella vaccines have been developed. Brucella suis S2, a live attenuated vaccine strain proven safe to humans, is widely used in China. In this report, a 77-year-old woman with a history of coughing and expectoration for three years was diagnosed with brucellosis by next-generation sequencing. Subsequently, the Brucella isolate from this patient was determined to be Brucella suis vaccine strain S2 by phage lysis experiments, quantitative real-time PCR, and third-generation sequencing. Its nucleotide identity with vaccine strain S2 was as high as 99.9996%, and only 14 deletion/insertion mutations or single nucleotide polymorphisms were detected. A phylogenetic tree constructed based on the genome sequences revealed that this strain clustered together with strain S2. As the patient denied having a history of contact with animals or exposure to other known sources, an epidemiological investigation was carried out on environmental and food samples. The results did not reveal a clear infection source except for a B. suis S2-like strain (99.9939% identity to B. suis S2 strain) from a milk sample. Our study may provide the first reliable evidence that B. suis vaccine strain S2 has the potential to infect humans. While this needs further confirmation, it points to the need to survey the virulence and risks of vaccine strain S2 in humans. In addition, the route of transmission of vaccine strain S2 still needs to be clarified to prevent more cases of brucellosis originating from this strain.

PMID 42504691
阅读全文 →
PubMedVaccines2026-07-27

Strain Matching of Seasonal Influenza Vaccines and Emergence of Neuraminidase Inhibitor Resistance in China from 2015 to 2025.

He Peiqing P, Luo Junhao J, Pu Siyu S, Cui Simin S et al.

Background: Influenza remains a major global public health threat, and vaccination is one of the most effective preventive measures. However, frequent antigenic drift and occasional antigenic shift, along with the lead time required for vaccine development and regional differences in the evolution of circulating strains, may lead to mismatches between WHO-recommended vaccine strains and circulating viruses. In addition, antiviral resistance further complicates precise influenza prevention and control. Objectives: This study aimed to evaluate the concordance of vaccine strains with circulating influenza viruses and the emergence of neuraminidase inhibitor (NAI) resistance in China. Methods: Data on antigenic characterization and antiviral susceptibility testing were extracted from weekly influenza surveillance reports published by the Chinese National Influenza Center from 2015 to 2025. Viral evolution, substitutions at key antigenic sites, and resistance-associated mutations were further examined based on sequences of circulating influenza viruses in China. Results: The overall vaccine match rates were 95.72% (95% CI: 94.02-97.43%) for A(H1N1)pdm09, 58.96% (95% CI: 54.93-62.96%) for A(H3N2), 64.45% (95% CI: 59.49-69.41%) for B/Victoria, and 95.19% (95% CI: 91.32-99.05%) for B/Yamagata in China during the 2015-2025 influenza seasons, with marked year-to-year fluctuations observed particularly for A(H3N2) and B/Victoria. The vaccine matching for cell-based A(H3N2) (70.41%, 95% CI: 65.04-75.77%) vaccine reference strains was significantly higher than that for egg-based A(H3N2) (48.09%, 95% CI: 42.63-53.55%) vaccine reference strains. Sequence analysis indicated that circulating A(H3N2) viruses showed the greatest genetic divergence from the matched egg-based vaccine strains (2.71%, 95% CI: 2.66-2.75%). Phenotypic NAI resistance was detected only in A(H1N1)pdm09 viruses, with resistance rates of 0.18% (95% CI: 0.07-0.45%) in 2023, 3.47% (95% CI: 2.63-4.57%) in 2024, and 3.01% (95% CI: 2.46-3.68%) in 2025. Neuraminidase (NA) sequence analysis showed that the key NAI resistance-associated substitution H274Y has been detected in A(H1N1)pdm09 viruses since 2015, at relatively high frequencies observed during 2015-2018. The mutation re-emerged in 2023 and presented increase trends thereafter, although no A(H1N1) pdm09 circulated during the COVID-19 pandemic. Conclusions: Antigenic concordance between vaccine strains and circulating A(H3N2) or B/Victoria viruses showed marked year-to-year fluctuations in China. Cell-based A(H3N2) vaccine reference strains showed higher antigenic concordance than egg-based strains, supporting further consideration of vaccine production platforms in A(H3N2)-predominant seasons. Phenotypic NAI resistance in circulating A(H1N1)pdm09 viruses was detected from 2023 onward in China, whereas resistance-associated NA substitutions had been detected earlier at the sequence level.

PMID 42506623
阅读全文 →
PubMedVaccines2026-07-27

Getting the Hepatitis B Birth Dose Vaccine to Every Baby: A Rapid Scoping Review of Birth Dose Vaccine Delivery Strategies in Out-of-Facility Settings.

Knudson Sophia S, Meghani Ankita A, Shelley Katharine D KD, Mossie Muluneh Yigzaw MY et al.

Globally, coverage of the hepatitis B vaccine within 24 h of birth is 45 percent, far below the WHO target of 90 percent by 2030. For newborns delivered in out-of-facility settings, delayed contact with health workers, transportation barriers, and cold chain constraints can impede timely vaccination. This review explores strategies and facilitators for delivering birth dose vaccines to infants born outside of health facilities in low- and middle-income countries. A rapid scoping review was conducted, searching PubMed and targeted websites for peer-reviewed and gray literature published between 2005 and 2025. Data were charted using a standardized extraction tool. Frequency and thematic analyses were conducted. After screening 315 studies, 26 eligible sources were identified. Delivery strategies consisted of three components: identifying and tracking home births; supporting caregiver uptake through education, reminders, or incentives; and delivering the vaccine through home-based administration or referral to facilities. Sub-components included pregnancy and birth notification systems, postnatal home visits, mobile reminders, incentives, and home-based vaccination by facility or community providers. The feasibility of these strategies was shaped by factors across system levels, such as national policies and financing; health system infrastructure; cold chain capacity; health workforce configuration; caregiver awareness; and community social norms. In several contexts, flexible cold chain approaches and vaccine administration by community-based cadres enabled timely vaccination of infants born at home. Vaccination programs can learn from existing out-of-facility vaccine delivery approaches to strengthen hepatitis B birth dose vaccination programs for timely and equitable coverage.

PMID 42506591
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal B vaccine